All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

COMy 2023

Share:

May 11, 2023

X post image

14 Jun 2023

During #COMy23, Luciano Costa, @End_myeloma discussed the rationale of using MRD-driven therapy in different clinical settings for patients with #multiplemyeloma.

Read our article to find out more 👇

#MMsm #myeloma
https://t.co/OCfdApFdVE

X post image

27 May 2023

The Multiple Myeloma Hub covered #COMy23 live on our socials!

You can find all the latest updates from COMy, including key insights and data presented, on our hub here.

👉 https://t.co/xBA7CI2X94

#mmsm #myeloma #CART #bispecifics @COMyCongress

X post image

14 May 2023

CONGRESS | #COMy23 | Cyrille Touzeau, @CHUNantes provided the updated phase IB study results of the MajesTEC-2 study assessing teclistamab combined with SC dara and lena in RRMM; promising clinical activity was observed (ORR: 93.5% and rapid time to first response: 1 month) #mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | @mvmateos presented the phase 1/2 MonumenTAL-1 results on talquetamab in heavily pre-treated patients with RRMM, demonstrating an ORR of >70%, median DOR:≥ 9 months, and a manageable safety profile overall #myeloma #mmsm #medicalcongress

X post image

14 May 2023

CONGRESS | #COMy23 | Philippe Moreau, @CHUnantes shared some correlative analyses on teclistamab for patients with RRMM (MAJESTEC-1 study) which highlighted the importance of the baseline immune profile on clinical responses #mmsm #myeloma #medicalcongress

X post image

14 May 2023

CONGRESS | #COMy23 | @paurotero shared updated 18-month follow-up data on ‘cohort C’ from the CARTITUDE-2 trial. Cilta-cel showed a clinical benefit in pts with heavily pre-treated RRMM and prior exposure to anti-BCMA therapy. ORR:60% in full cohort and MRD negativity: 70% #mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | Pieter Sonneveld, @ErasmusMC presented the 18-month follow-up data on 'cohort B' of the CARTITUDE-2 study assessing cilta-cel in patients with early relapse, ≤ 12 months after prior therapy. ORR:100% with 90% achieving CR; safety profile was manageable
#mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | @YimerHabte shared updated subgroup analyses by age and frailty from the full US MM-6 study on transitioning from bortezomib-based induction to IRd in patients with NDMM; demonstrating an improved depth of response and tolerable safety profile overall #mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | @JoshuaRichterMD,
@MountSinaiNYC presented clinical data on the phase 1/2 first in-human study on linvoseltamab for RRMM. At recommended dose of 200mg, ORR was 64%. MRD negativity rate of 60% seen in phase 2 and a manageable safety profile overall #myeloma

X post image

14 May 2023

CONGRESS | #COMy23 | Ajay K. Nooka, @WinshipAtEmory presented 3-year follow up results from the phase II DREAMM-2 study assessing belantamab mafodotin for RRMM. Clinically meaningful responses were observed with no new safety signals compared to earlier analyses #mmsm #myeloma

X post image

14 May 2023

CONGRESS | #COMy23 | Evangelos Terpos, @uoaofficial presented the phase 1/2 BelaRd study results on belantamab mafodotin plus lena/dexamethasone in transplant-ineligible patients with NDMM; deep and durable responses with no PD and minimal impact on vision function observed #mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | @AtrashShebli presented final results from the first in-human phase 1/2 study on modakafusp alfa in patients with RRMM; promising efficacy shown (ORR: 43%). Q4W is the optimal dosing interval with studies ongoing to establish optimal single-agent dose #mmsm

X post image

14 May 2023

CONGRESS | #COMy23 | Cyrille Touzeau, @CHUNantes provided updated phase I study results on IV and SC dosing of forimtamig in patients with RRMM; high activity (ORR: 71.4% vs 63.6%) and durable responses (median DOR, 10.8 vs 12.5 months) observed for IV vs SC arm. #mmsm #myeloma

X post image

14 May 2023

CONGRESS | #COMy23 | @JoshuaRichterMD, @MountSinaiNYC presented early data from a phase I study on fixed duration cevostamab in patients with heavily pre-treated RRMM; durable responses observed (>12 month), with most responders exhibiting disease control after retreatment #mmsm

X post image

13 May 2023

CONGRESS | #COMy23 | Salomon Manier,
@CHU_Lille gave a fantastic talk on optimal sequencing of bispecifics and CAR T-cell therapy in MM highlighting the need to understand resistance mechanisms, T-cell exhaustion, and whether to switch targets after BCMA-directed therapies? #mmsm

X post image

13 May 2023

CONGRESS | #COMy23 | @mbeksac56 of @AnkaraUni_en gave a nice overview on supportive care strategies for immunotherapy-related toxicities in MM, including clinical management of CRS, cytopenias, and infections
#multiplemyeloma #mmsm #medicalcongress

X post image

13 May 2023

CONGRESS | #COMy23 | @NoopurRajeMD
from @harvardmed highlighted the efficacy and safety data on CAR T-cell therapies in the RRMM setting
#mmsm #myeloma #medicalcongress

X post image

13 May 2023

CONGRESS | #COMy23 | Saad Usmani
@szusmani from @MSKCancerCenter
discussed the use of bispecifics in RRMM, highlighting its pros, cons, and future studies in this setting
#mmsm #myeloma #medicalcongress

X post image

13 May 2023

CONGRESS | #COMy23 | @PerrotAurore from the Toulouse University Hospital presented the clinical case of a patient with triple-class RRMM highlighting the issues and clinical approach involving different lines of therapies #myeloma #mmsm #medicalcongress

X post image

13 May 2023

CONGRESS | #COMy23 | @SagarLonialMD, @WinshipAtEmory delivered a fascinating debate on whether we can use CAR T-cell therapy instead of ASCT in MM highlighting its advantages, disadvantages, and the need for PFS to exceed current treatment standards
#myeloma #mmsm

X post image

13 May 2023

CONGRESS | #COMy23 | Philippe Moreau, @CHUnantes delivered a talk on treatment approaches for a young and fit patient with NDMM who are transplant-eligible, including the use of quadruplet regimens and the ongoing risk-adapted strategies being studied in this area
#mmsm #myeloma

X post image

13 May 2023

CONGRESS | #COMy23 | Paul Richardson,
@Danafarber further discussed the clinical strategy for a young and fit patient with MM, highlighting important considerations, role of ASCT, non-transplant approaches, emerging role of quadruplet regimens and MRD #myeloma #mmsm

X post image

13 May 2023

CONGRESS | #COMy23 | Nisha Joseph, @WinshipAtEmory presented an interesting clinical case of a young and fit patient with multiple #myeloma discussing the recommended induction therapy and posing the question for what are optimal treatment options in this setting? #mmsm

X post image

13 May 2023

CONGRESS | #COMy23 | Heinz Ludwig of Wilhelminen Cancer Research Institute gave a talk on the clinical management of infections in elderly and frail patients with MM, highlighting how to select patients and important prophylactic measures and vaccinations #mmsm #myeloma

X post image

12 May 2023

CONGRESS | #COMy23 | @H_Einsele from @Uni_WUE provided insights on the ongoing studies, challenges, and future directions in the use of allogeneic transplantation and cellular therapies such as CAR T-cell therapy in MM
#mmsm #myeloma #medicalcongress

X post image

12 May 2023

CONGRESS | #COMy23 | Meletios Dimopoulos ,
@uoaofficial discussed the recent advances in the novel CELMoD agents mezigdomide and iberdomide for patients with MM, highlighting the encouraging clinical data on their combinations
#myeloma #mmsm #medicalcongress

X post image

12 May 2023

CONGRESS | #COMy23 | Luciano Costa, @End_myeloma from @uabmedicine
discussed MRD-driven treatment approaches in MM relative to different settings including post-transplant, during maintenance therapy, and on resurgence of MRD #mmsm #myeloma #medicalcongress

X post image

12 May 2023

CONGRESS | #COMy23 | Jesús San Miguel,
@unav discussed the controversies in the use of MRD in MM including CR, unsustained MRD, time to achieve MRD negativity, and hemodilution followed by a ‘how I use MRD in my clinical practice’ approach

#mmsm #myeloma

X post image

12 May 2023

CONGRESS | #COMy23 | Marc Raab,
@UniHeidelberg discussed promising data on molecular-based personalized treatments in MM highlighting the future direction in molecular diagnostics #mmsm #myeloma #medicalcongress

X post image

12 May 2023

CONGRESS | #COMy23 | @BrunoPaiva_UNAV of @CIMA_unav, @ClinicaNavarra shared some technical tips in performing a reliable MRD assessment in multiple #myeloma considering the how, when, and which patients should undergo MRD monitoring
#mmsm #medicalcongress

X post image

11 May 2023

CONGRESS | #COMy23 | @mvmateos delivered a fascinating discussion on whether we should treat smoldering MM, taking into consideration the risk of progression to MM based on clinical and biological biomarkers and data from early intervention studies
#mmsm #myeloma

X post image

11 May 2023

CONGRESS | #COMy23 | @EileenMBoyle from @Perlmutter_CC discussed the criteria for defining smoldering MM, including multiple factors such as genetics and microenvironment implicated in the risk of progression from SM to MM
#mmsm #myeloma #medicalcongress

X post image

11 May 2023

CONGRESS | #COMy23 | @IreneGhobrial from @DanaFarber discussed the criteria for defining precursor conditions in MM, including the risk factors for progression from MGUS and SMM to MM

#mmsm #myeloma #medicalcongress

X post image

11 May 2023

#COMy23 #myeloma #mmsm https://t.co/uPZe9sQaa1

X post image

11 May 2023

CONGRESS | #COMy23 | Elena Zamagni from @Unibo shares interesting insights into the latest imaging advances to prognosticate clinical outcomes following treatment in MM
#mmsm #myeloma #medicalcongress

X post image

11 May 2023

CONGRESS | #COMy23 | @myelomaMD of @MayoClinic gives an overview of the staging approaches in MM, highlighting the increasing need for integration of more prognostic factors
#mmsm #myeloma #medicalcongress

X post image

11 May 2023

CONGRESS | #COMy23 | @Florent_Malard of @Sorbonne_Univ_ discussed the influences of gut microbiota in MM, highlighting the need for further studies in this area #mmsm #myeloma #medicalcongress

X post image

11 May 2023

CONGRESS | #COMy23 | Dr Paola Neri of @UCalgaryMed @Charb_Cancer described how changes in the BM microenvironment contributes to MM progression
#mmsm #myeloma #medicalcongress

X post image

10 May 2023

📢 CONGRESS | The @MM_Hub will be attending #COMy23.

📅 May 11–14, 2023  

📍 Paris

Keep an eye on our socials for live coverage throughout the congress!

#mmsm #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

COMy 2023 Controversies in Multiple Myeloma

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox